The UC Davis Department of Obstetrics and Gynecology is recruiting potential participants for a clinical trial of an investigational hormone-free monthly intravaginal method of contraception.
Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization, showcased cutting-edge breast cancer research aimed at advancing the field at the ASCO Annual Meeting 2024. Organized by the American Society of Clinical Oncology, this premier conference annually convenes over 40,000 oncologists and stakeholders worldwide.
In a substantial milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory (LLNL) and BridgeBio Oncology Therapeutics (BridgeBio) today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer.
Clinical Trial Finds Oral Medication Significantly Reduced Prurigo Nodularis and Chronic Pruritus of Unknown Origin Symptoms A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study published in JAMA Dermatology.
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for vitamin D levels, according to a new Clinical Practice Guideline issued today by the Endocrine Society.
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
Researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease. The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
Up to 18% of patients undergoing ACL reconstruction experience graft failure and require revision surgery, which is known to increase the risk of developing post-traumatic osteoarthritis (PTOA).
The University of Illinois Chicago study will be the first to assess whether the natural product has anti-cancer effects that could benefit patients as they await surgical treatment.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications.
Dr. Hyuk-June Moon from the Bionics Research Center at the Korea Institute of Science and Technology (KIST), in collaboration with Prof. Olaf Blanke’s team at the Swiss Federal Institute of Technology Lausanne (EPFL), has successfully induced self-location illusions with multi-sensory virtual reality (VR) in the MRI scanner and observed corresponding changes in the human brain's grid cell activity.
A recent publication in Scientific Reports unveils a potentially groundbreaking non-opioid pain treatment developed by a team led by Dr. Hernan Bazan.
Randomized controlled trials have long been the gold standard for evaluating new therapies. But for pediatric brain tumors, it can be difficult—if not impossible—to enroll the large numbers of patients needed for these studies.
Sylvester Comprehensive Cancer Center today announced establishment of the Sylvester Brain Tumor Institute. It will focus on personalized medicine approaches for treating all patients with brain tumors.
ChatGPT, the artificial intelligence (AI) chatbot designed to assist with language-based tasks, can effectively extract data for research purposes from physicians' clinical notes, UT Southwestern Medical Center researchers report in a new study. Their findings, published in NPJ Digital Medicine, could significantly accelerate clinical research and lead to new innovations in computerized clinical decision-making aids.
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to the ”Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage (E-MOTIVE).”
The first U.S. heart patient involved in a study for a new gene-editing therapy has successfully been treated at MedStar Washington Hospital Center.
The Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai Cancer, is teaming up with the AIM at Melanoma Foundation for the 14th year to host a free melanoma symposium for patients, caregivers and clinicians.
Patients in South Florida with metastatic melanoma will soon have access to tumor-infiltrating lymphocyte therapy, or TIL. The therapy will be available at Sylvester Comprehensive Cancer Center and will be South Florida’s only center offering this treatment.
Researchers at Wake Forest University School of Medicine have been approved for a $1 million award by the Patient-Centered Outcomes Research Institute (PCORI) for a methodology study.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for April 2024.
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy.
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
The Wilmer Eye Institute, Johns Hopkins Medicine has received two awards totaling more than $20 million from the National Eye Institute at the National Institutes of Health, both of which will be used for a six-year clinical trial investigating a potential treatment for the most common inherited retinal disease, retinitis pigmentosa.
Curtis L. Cetrulo Jr., MD, vice chair of Research in the Department of Surgery and director of the Division of Plastic Surgery, has been selected as the General William and Willa Dean Lyon Family Chair in Reconstructive and Plastic Surgery.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer in the U.S., or 21.9%, participate in some form of clinical research.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
A 'Comprehensive Cancer Center' is the top U.S. designation for cancer research and treatment facilities recognized by high-quality research that leads to major shifts in cancer care.
A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.
A gene therapy developed by researchers at UT Southwestern Medical Center for a rare disease called giant axonal neuropathy (GAN) was well tolerated in pediatric patients and showed clear benefits, a new study reports. Findings from the phase one clinical trial, published in the New England Journal of Medicine, could offer hope for patients with this rare condition and a host of other neurological diseases.
UCI Health, the clinical enterprise of the University of California, Irvine, has completed the acquisition of four hospitals and associated outpatient locations from Tenet Healthcare Corporation.
Mariam F. Eskander, MD, MPH, surgical oncologist in the Gastrointestinal Oncology Program at Rutgers Institute of New Jersey, offers insight and tips for minority individuals navigating a cancer diagnosis and how we can all work together to mitigate cancer disparities.
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
For years, it was harder for Black patients to secure a coveted spot on the national kidney transplant waitlist because a clinical algorithm was making Black patients appear healthier than they were.
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI), part of the National Institutes of Health.
ScienceMedia, a global SaaS provider redefining the landscape of clinical mastery in the biotech and pharma industries, announces the formation of its inaugural advisory board.
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
The ATS 2024 International Conference Program is now live! Get ready for a series of dynamic scientific programming with presentations covering AI in thoracic medicine, the basic sciences, research breakthroughs and clinical treatment, as well as spotlighting the next generation of innovators in pulmonary, critical care and sleep medicine.
In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity.
Scientists at St. Jude Children’s Research Hospital have uncovered a metabolic role for cell-survival protein MCL-1, potentially explaining previous clinical trial setbacks.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
